USARx offers multiple ways to purchase this medication. Choose the Best option for you!
Applies to cefazolin: injection powder for solution
Along with its needed effects, cefazolin may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor or nurse immediately if any of the following side effects occur while taking cefazolin:
Incidence not known
Some side effects of cefazolin may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Incidence not known
Applies to cefazolin: injectable powder for injection, injectable solution, intravenous powder for injection, intravenous solution
Common (1% to 10%): Diarrhea, vomiting, nausea
Uncommon (0.1% to 1%): Oral candidiasis (oral thrush)
Very rare (less than 0.01%): Anal pruritus, pseudomembranous colitis
Frequency not reported: Mouth ulcers, abdominal/stomach cramps, epigastric pain, heartburn, flatus, Clostridium difficile-associated diarrhea, colitis
Frequency not reported: Colitis, abdominal pain
Diarrhea, nausea, vomiting, and loss of appetite were usually of moderate severity and frequently resolved during or after therapy.
Oral candidiasis has been reported during prolonged therapy.
The onset of pseudomembranous colitis symptoms has been reported during or after antibacterial therapy.
Common (1% to 10%): Loss of appetite
Rare (0.01% to 0.1%): Increased blood glucose level/hyperglycemia, decreased blood glucose level/hypoglycemia
Frequency not reported: Anorexia
Common (1% to 10%): Pain at IM injection site (sometimes with induration)
Uncommon (0.1% to 1%): Thrombophlebitis with IV administration
Frequency not reported: Phlebitis at injection site, induration
Uncommon (0.1% to 1%): Erythema, erythema multiforme, exanthema, urticaria, angioedema (reversible local permeability of blood vessels, joints, mucous membranes)
Rare (0.01% to 0.1%): Toxic epidermal necrolysis (Lyell's syndrome), Stevens-Johnson syndrome
Frequency not reported: Pruritus, skin rash, fixed drug eruptions, pustular skin eruptions, contact dermatitis
-Frequency not reported: Urticaria, Stevens-Johnson syndrome, erythema multiforme, toxic epidermal necrolysis
A case of occupational contact dermatitis due to cephalosporin allergy has been reported in a nurse who prepared cephalosporin solutions for administration to patients. The dermatitis resolved after the nurse stopped preparing the solutions.
Uncommon (0.1% to 1%): Seizures
Rare (0.01% to 0.1%): Dizziness, vertigo, hyperactivity, drowsiness, epileptogenic activity
Frequency not reported: Fainting, lightheadedness, somnolence, headache, encephalopathy (symptoms included tonic-clonic seizures, lethargy, disorientation, memory loss, asterixis, multifocal myoclonus)
-Frequency not reported: Hyperactivity, hypertonia
Seizures have been reported when inappropriately high doses were administered to patients with renal dysfunction (CrCl less than 55 mL/min).
Encephalopathy has been reported in patients with renal failure. Toxicity was due to increased drug serum levels and increased permeability of blood-brain barrier caused by uremia.
Uncommon (0.1% to 1%): Drug-induced fever
Rare (0.01% to 0.1%): Malaise, fatigue, weakness, hot flushes, chest pain, increased LDH, increased alkaline phosphatase
Very rare (less than 0.01%): Face edema
Frequency not reported: Tiredness
-Frequency not reported: Elevated LDH, superinfection, false-positive test for urinary glucose
Uncommon (0.1% to 1%): Interstitial pneumonia/pneumonitis
Rare (0.01% to 0.1%): Pleural effusion, dyspnea, respiratory distress, cough, rhinitis
Risk factors for coagulation disorders have included insufficient vitamin K or other blood clotting factors, artificial nutrition, poor diet, liver or renal dysfunction, thrombocytopenia, and disorders/diseases that cause bleeding (e.g., hemophilia, stomach ulcers, duodenal ulcers).
A 26-year-old hemodialysis patient with a coagulase-positive staphylococcal arteriovenous fistula graft infection was found to have a hematoma and increased thrombin, prothrombin, and partial thromboplastin times after receiving 1 g IV followed by 0.5 g every 8 hours for 12 days. The laboratory changes resolved after therapy was stopped, but recurred when this drug was reinstituted.
Rare (0.01% to 0.1%): Neutropenia, leukopenia, thrombocytopenia, granulocytopenia, leukocytosis, granulocytosis, monocytosis, lymphocytopenia, basophilia, eosinophilia
Very rare (less than 0.01%): Coagulation (blood clotting) disorders, bleeding, decreased hemoglobin, decreased hematocrit, anemia, agranulocytosis, aplastic anemia, pancytopenia, hemolytic anemia
Frequency not reported: Thrombocythemia, hematoma, increased thrombin time, increased prothrombin time, increased partial thromboplastin time, positive direct and indirect Coombs tests
-Frequency not reported: Aplastic anemia, hemolytic anemia, hemorrhage, prolonged prothrombin time, pancytopenia, agranulocytosis
Transient increases in AST, ALT, GGT, bilirubin, LDH, and alkaline phosphatase have been reported.
Rare (0.01% to 0.1%): Increased AST, increased ALT, increased GGT, increased bilirubin, hepatitis (transient), cholestatic jaundice (transient)
Frequency not reported: Hepatic dysfunction (including cholestasis), elevated bilirubin
Transient increases in BUN were generally reported in patients using other potentially nephrotoxic agents concomitantly.
Rare (0.01% to 0.1%): Nephrotoxicity, interstitial nephritis, undefined nephropathy, increased BUN (transient)
Frequency not reported: Increased creatinine levels, renal failure, increased serum urea
-Frequency not reported: Renal dysfunction, toxic nephropathy, increased creatinine, interstitial nephritis (reversible fever, azotemia, pyuria, eosinophiluria; with some cephalosporins)
Rare (0.01% to 0.1%): Vaginitis, genital candidiasis (moniliasis), proteinuria
Very rare (less than 0.01%): Genital pruritus
Frequency not reported: Vulvar pruritus
Rare (0.01% to 0.1%): Nightmares, nervousness/anxiety, insomnia, confusion
Rare (0.01% to 0.1%): Disturbed color vision
Very rare (less than 0.01%): Anaphylactic shock (including swelling of larynx with narrowing of airways, increased heart rate, shortness of breath, falling blood pressure, swollen tongue)
Frequency not reported: Anaphylaxis, allergic reaction (including eosinophilia, urticaria, itching, drug fever, skin rash, Stevens-Johnson syndrome), allergic cross-sensitivity
-Frequency not reported: Allergic reactions, serum sickness-like reaction
Frequency not reported: Hypotension
June 25, 2020
June 23, 2020
June 22, 2020
June 18, 2020
June 17, 2020
June 4, 2020